heritag global inc hgbl buy pt busi sell distress asset current environ posit initi
coverag buy rate pt analyst michael diana full summari
navidea biopharmaceut inc navb buy pt arm data posit derisk tc-til rais pt
appili inc apli buy pt focu treat appili move target
inc hold back basic look growth focu back filgotinib posit data
corpor event pleas contact maxim salesperson inform
maxim group virtual confer apdn bioc bngo capr codx dxr koligo privat meso
psti vnrx host mccarthi vendetti wed may
navb share pre-market releas posit
preliminari data arm trial tc-til rheumatoid
arthriti ra data pilot arm could view
potenti outlin pivot trial see data de-risk
event lower risk adjust tctil model
rais pt
arm measur magnitud chang tilmanocept uptak valu tuv
patient initi anti-tnf therapi baselin week
clinic assess week tradit measur treatment effect
determin tc-til provid earli quantit assess treatment
patient complet assess
tuv predict treatment respons anti-tnf respond
tuv declin non-respond increas
navidea engag advanc partnership discuss
arm data hand believ navidea stronger posit
secur right deal commerci partner
conclus arm data demonstr tc-til imag
repeat reproduc stabl arm data provid proof
concept underli hypothesi tc-til provid earli
quantit measur respons treatment asset somewhat de-
risk view
arm data potenti readthrough arm data
phase trial import mileston devlop asset
interim analysi arm healthi subject patient
stabl diseas abl confirm repeat reproduc stabil tc-
til imag establish quantit measur healthi vs ra joint
arm design mirror phase demonstr tc-til identifi
respond anti-tnf treatment week compar standard week
requir tradit clinic assess patient arm candid
move anti-tnf biolog therapi assess whether tc-til
measur respons anti-tnf
interim analysi perform enrol patient includ
incud baselin measur week measur week
measur patient far well clinic analys subject
reach week demonstr chang tilmanocept imag week
predict respons therapi clinic assess week one
patient concord chang treatment studi somewhat
confound data
averag patient respond averag declin tilmanocept
signal observ increas observ non-respond
importantli trend increas signal non-respond decreas
signal respond consist across patient consid magnitud
effect tc-til may actual applic even earlier week though data
earli would requir addit data determin overal dynam
rang observ global tuv inflam joint patient
combin low variabl signal quantif arm support
clinic continu page
click full note
busi sell distress asset current
environ posit initi coverag buy
rate pt
heritag global core busi broker charged-off consum
loan auction surplu industri asset increas
demand busi heritag global relat busi
compani profit cash flow posit significantli under-valued
ebitda estim initi coverag buy rate pt
repres ebitda still discount best peer
heritag global four main line busi descend order import
broker charged-off consum loan heritag nation loan
exchang nlex subsidiari dispos surplu industri asset mainli plant
equip machineri princip buyer agent auction heritag
global partner act lender buyer charged-off consum loan
heritag global capit provid fee-bas valuat servic lender
mainli bank regard industri equip held loan collater heritag
busi diversifi yet synergist nlex heritag global
partner well known lead posit start renown
industri figur ross dove ceo kirk dove busi
also pro-cycl counter-cycl
growth driver current weak economi present
counter-cycl opportun heritag global view nlex heritag
global capit benefit charged-off loan sold financi
institut though probabl lower price surplu equip sale plant
closur drive higher auction volum bank lender like
need refresh valuat industri equip collater note
heritag global sale activ includ auction on-line
long-term growth driver manag consid best nlex growth
opportun fintech among fintech compani succeed
loan sale grow also fintech fail higher rate succeed
also gener busi liquid heritag global
partner growth includ sign larg compani current client
forward flow agreement gener recur auction
win larg sale industri asset transact act
princip manag believ newest busi heritag global capit
could fastest grow busi next year take advantag
nlex relationship
earn revenu growth estim compar estim
includ weak actual result repres growth total revenu
growth adjust ebitda growth ep note sell-
side firm cover stock compani hit adjust ebitda estim
substanti increas valuat
ebitda share significantli under-valued view
publicli trade auction compani close compar
global heritag view focu one nich relev
compar howev see figur page price target heritag
global ev/ebitda multipl would repres discount
ev/ebitda multipl best peer nr view heritag
global trade premium discount given heritag
global longer stronger profit
click full note
